Eribulin

BNF:
8.1.5
Status:
Do Not Prescribe (DNP), Red
Decision Date:
January 2017
 

Comments

RED:1,2,3: NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens.

DO NOT PRESCRIBE (DNP)6: NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen. (Decision date - April 2018)  

NHSE are the responsible commissioner for this drug.

Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app